Omadacycline

Brand names: Nuzyra · Active ingredient: Omadacycline

In short: NUZYRA is indicated for the treatment of adult patients with community-acquired bacterial pneumonia (CABP) caused by the following susceptible microorganisms: Streptococcus pneumoniae, Staphylococcus aureus(methicillin-susceptible isolates), Haemophilus influenzae, Haemophilus parainfluenzae, Klebsi

Forms & strengthsEach single-dose vial contains 100 mg omadacycline (equivalent to 131 mg omadacycline tosylate) which must be reconstituted and further diluted prior to intravenous infusion. The lyophilized powder is a yellow to dark orange cake. …
LabelParatek Pharmaceuticals, Inc.
Label updatedMay 28, 2026

What is Omadacycline used for?

NUZYRA is indicated for the treatment of adult patients with community-acquired bacterial pneumonia (CABP) caused by the following susceptible microorganisms:

Streptococcus pneumoniae,

Staphylococcus aureus(methicillin-susceptible isolates),

Haemophilus influenzae,

Haemophilus parainfluenzae,

Klebsiella pneumoniae, Legionella pneumophila,

Mycoplasma pneumoniae,and

Chlamydophila pneumoniae.

NUZYRA is indicated for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI) caused by the following susceptible microorganisms:

Staphylococcus aureus(methicillin-susceptible and -resistant isolates),

Staphylococcus lugdunensis,

Streptococcus pyogenes, Streptococcus anginosusgrp. (includes

S. anginosus,

S. intermedius, and

S. constellatus),

Enterococcus faecalis,

Enterobacter cloacae,and

Klebsiella pneumoniae.

To reduce the development of drug-resistant bacteria and maintain the effectiveness of NUZYRA and other antibacterial drugs, NUZYRA should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Omadacycline dosage

NUZYRA for Injection: Do NOT administer NUZYRA for injection with any solution containing multivalent cations, e.g., calcium and magnesium, through the same intravenous line

. Co-infusion with other medications has not been studied

.

NUZYRA Tablets: Fast for at least 4 hours and then take with water. After oral dosing, no food or drink (except water) is to be consumed for 2 hours and no dairy products, antacids, or multivitamins for 4 hours

.

For treatment of adults with CABP the recommended dosage regimen (loading and maintenance) of NUZYRA is described in

Table 1 below.

Loading Doses | Maintenance Dose | Treatment Duration

NUZYRA Injection:

200 mg by

intravenousinfusion over 60 minutes on day 1.

OR

100 mg by

intravenousinfusion over 30 minutes, twice on day 1.

OR | NUZYRA Injection:

100 mg by

intravenousinfusion over 30 minutes once daily.

OR

NUZYRA Tablets:

300 mg

orallyonce daily. | 7 to 14 Days

NUZYRA Tablets:

300 mg

orally twiceon day 1.

For treatment of adults with ABSSSI, the recommended dosage regimen (loading and maintenance) of NUZYRA is described in

Table 2 below.

Loading Doses | Maintenance Dose | Treatment Duration

NUZYRA Injection:

200 mg by

intravenousinfusion over 60 minutes on day 1.

OR

100 mg by

intravenousinfusion over 30 minutes, twice on day 1.

OR | NUZYRA Injection:

100 mg by

intravenousinfusion over 30 minutes once daily.

OR

NUZYRA Tablets:

300 mg

orallyonce daily. | 7 to 14 Days

NUZYRA Tablets:

450 mg

orallyonce a day on day 1 and day 2.

No dosage adjustment is warranted in patients with renal or hepatic impairment

.

Reconstitution and Dilution:

NUZYRA must be reconstituted and then further diluted under aseptic conditions. To prepare the required dose for intravenous infusion, reconstitute and dilute the appropriate number of vials, as determined from

Table 3 below.

Reconstitute each 100 mg vial of NUZYRA with 5 mL of Sterile Water, 0.9% Sodium Chloride Injection, USP, or 5% Dextrose Injection, USP, for Injection.

Gently swirl the contents and let the vial stand until the cake has completely dissolved and any foam disperses. Do not shake the vial.

The reconstituted NUZYRA solution should be yellow to dark orange in color; if not, the solution should be discarded. Visually inspect the reconstituted NUZYRA solution for particulate matter and discoloration prior to further dilution and administration. If necessary, invert the vial to dissolve any remaining powder and swirl gently to prevent foaming.

Immediately (within 1 hour), withdraw 5 mL or 10 mL of the reconstituted solution and further dilute to a 100 mL (nominal volume) of 0.9% Sodium Chloride Injection, USP, or 5% Dextrose Injection, USP, bag for injection. …

How to take Omadacycline — instructions & advice from the label

Nausea and Vomiting

Advise patients that nausea and vomiting can be an adverse reaction to NUZYRA. Advise patients that a greater proportion of patients who received the oral loading dose of NUZYRA for treatment of ABSSSI experienced nausea and vomiting.

Allergic Reactions

Advise patients that allergic reactions, including serious allergic reactions, could occur and that serious allergic reactions require immediate treatment. Ask the patient about any previous hypersensitivity reactions to NUZYRA, or other tetracycline class antibacterials

.

Administration with Food

Instruct patients to fast 4 hours before and 2 hours after taking NUZYRA tablets and not to consume dairy products, antacids, or multivitamins for 4 hours after taking NUZYRA tablets

.

Tooth Discoloration and Inhibition of Bone Growth

Advise patients that NUZYRA, like other tetracycline class drugs, may cause permanent tooth discoloration of deciduous teeth and reversible inhibition of bone growth when administered during the second and third trimesters of pregnancy. Tell your healthcare provider right away if you become pregnant during treatment

. …

Warnings & precautions

Do not take this medicine if: NUZYRA is contraindicated in patients with known hypersensitivity to omadacycline or tetracycline class antibacterial drugs, or to any of the excipients

.

The use of NUZYRA during tooth development (last half of pregnancy, infancy, and childhood up to the age of 8 years) may cause permanent discoloration of the teeth (yellow-gray-brown). This adverse reaction is more common during long-term use of the tetracycline class drugs, but it has been observed following repeated short-term courses. Enamel hypoplasia has also been reported with tetracycline class drugs. Advise the patient of the potential risk to the fetus if NUZYRA is used during the second or third trimester of pregnancy

.

The use of NUZYRA during the second and third trimester of pregnancy, infancy and childhood up to the age of 8 years may cause reversible inhibition of bone growth. All tetracyclines form a stable calcium complex in any bone-forming tissue. A decrease in fibula growth rate has been observed in premature infants given oral tetracycline in doses of 25 mg/kg every 6 hours. This reaction was shown to be reversible when the drug was discontinued. Advise the patient of the potential risk to the fetus if NUZYRA is used during the second or third trimester of pregnancy

.

Hypersensitivity reactions have been reported with NUZYRA

.

Life-threatening hypersensitivity (anaphylactic) reactions have been reported with other tetracycline class antibacterial drugs. NUZYRA is structurally similar to other tetracycline class antibacterial drugs and is contraindicated in patients with known hypersensitivity to tetracycline class antibacterial drugs

. Discontinue NUZYRA if an allergic reaction occurs.

Clostridioides difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents and may range in severity from mild diarrhea to fatal colitis. …

Omadacycline side effects

The following clinically significant adverse reactions are described in greater detail in the Warnings and Precautions section of labeling:

Tooth Development and Enamel Hypoplasia

Inhibition of Bone Growth

Hypersensitivity Reactions

Tetracycline Class Effects

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Overview of the Safety Evaluation of NUZYRA

NUZYRA was evaluated in three Phase 3 pivotal clinical trials (Trial 1, Trial 2 and Trial 3) and one Phase 3 postmarketing clinical trial (Trial 4). These trials included one pivotal Phase 3 trial in CABP patients (Trial 1), one Phase 3 postmarketing trial in CABP patients (Trial 4), and two pivotal Phase 3 trials in ABSSSI patients (Trial 2 and Trial 3). Across all Phase 3 trials, a total of 1409 patients were treated with NUZYRA. In Trials 2 and 3, 691 patients with ABSSSI received NUZYRA, of which 368 patients were treated with only oral NUZYRA. In Trials 1 and 4, 718 patients with CABP were treated with NUZYRA. …

Drug interactions

Because tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage while also taking NUZYRA.

Absorption of oral tetracyclines, including NUZYRA, is impaired by antacids containing aluminum, calcium, or magnesium, bismuth subsalicylate, and iron containing preparations

.

About this medicine

NUZYRA contains omadacycline tosylate, an aminomethylcycline which is a semisynthetic derivative of the tetracycline class of antibacterial drugs, for intravenous or oral administration. The chemical name of omadacycline tosylate is (4S,4aS,5aR,12aS)-4,7-bis(dimethylamino)-9-(2,2-dimethylpropylaminomethyl)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide, 4-methylbenzenesulfonate.

The molecular formula is C

36H

48N

4O

10S (monotosylate salt) and the molecular weight is 728.9 (monotosylate salt). The following represents the chemical structure of omadacycline tosylate:

NUZYRA (omadacycline) for injection is a yellow to dark orange sterile lyophilized powder. Each vial of NUZYRA for injection contains 100 mg of omadacycline (equivalent to 131 mg omadacycline tosylate). Inactive ingredients: Sucrose (100 mg); may include hydrochloric acid and/or sodium hydroxide for pH adjustment. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 51591524-4703-44c6-8bde-dce3e6a463d1. Read the full official label on DailyMed.

Related medicines

Amoxicillin Azithromycin Doxycycline Amoxicillin and Clavulanate Cephalexin Valacyclovir Sulfamethoxazole and Trimethoprim Nitrofurantoin